Literature DB >> 16704541

Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis.

Alberto Queiroz Farias1, Luciana Lofego Gonçalves, Paulo Lisboa Bittencourt, Evandro Sobroza De Melo, Clarice Pires Abrantes-Lemos, Gilda Porta, Maria Cristina Nakhle, Flair Jose Carrilho, Eduardo Luiz Rachid Cancado.   

Abstract

BACKGROUND AND AIMS: According to the International Autoimmune Hepatitis Group (IAIHG) criteria, circulating antimitochondrial antibodies (AMA) do not support the diagnosis of autoimmune hepatitis (AIH). The aims of this study were to characterize a subset of patients with AIH who have AMA and antiM2 seropositivity, and to assess the applicability of the revised scoring system of the IAIHG in the diagnosis of this variant form of AIH.
METHODS: Eighteen patients with AMA-AIH were enrolled and compared with 206 classical AIH and 85 primary biliary cirrhosis (PBC) controls. Human leukocyte antigen (HLA) class II alleles were determined by polymerase chain reaction (PCR) amplification with sequence-specific primers, and biopsies were blindly reevaluated.
RESULTS: The patients with AMA-AIH were, on average, older than patients with classical AIH and had an hepatocellular pattern of elevated liver enzymes, hypergammaglobulinemia and lower levels of cholesterol, when compared with PBC controls. There were no histological signs of PBC or overlapping forms in any AMA-AIH biopsies. The majority of patients with AMA-AIH carried HLA antigens associated with classical AIH (DRB1*03, n = 5; DRB1*04, n = 7, and DRB1*13, n = 6). Pretreatment scores classified all AMA-AIH patients with probable (n = 17) or improbable (n = 1) AIH. After treatment, only 28% of AMA-AIH patients reached scores for definite diagnosis, compared with 90.1% of AIH-1 and 96.4 AIH-2. In the AMA-AIH group, only patients who relapsed after immunosuppressive drug withdrawal could be classified with definite AIH.
CONCLUSIONS: AMA-AIH shares common features with classical AIH. The diagnosis of AMA-AIH may be swayed by the IAIHG criteria, rendering questionable the applicability of the revised scoring system to this variant form of AIH.

Entities:  

Mesh:

Year:  2006        PMID: 16704541     DOI: 10.1111/j.1440-1746.2006.04130.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Anti-mitochondrial M2 antibody-positive autoimmune hepatitis.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Kazunori Fugo; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2015-08-20       Impact factor: 2.447

Review 2.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 3.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

4.  Association of an overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis with cytomegalovirus infection.

Authors:  Megumi Toyoda-Akui; Hiroaki Yokomori; Fumihiko Kaneko; Yuki Shimizu; Hajime Takeuchi; Kumiko Tahara; Hide Yoshida; Hirobumi Kondo; Tadashi Motoori; Makoto Ohbu; Masaya Oda; Toshifumi Hibi
Journal:  Int J Gen Med       Date:  2011-05-24

5.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12

6.  The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders.

Authors:  Panagiotis A Papamichalis; Kalliopi Zachou; George K Koukoulis; Aikaterini Veloni; Efthimia G Karacosta; Lampros Kypri; Ioannis Mamaloudis; Stella Gabeta; Eirini I Rigopoulou; Ansgar W Lohse; George N Dalekos
Journal:  J Autoimmune Dis       Date:  2007-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.